Putting the award page together from the records…
Putting the award page together from the records…
4J Therapeutics Inc received this contract from Barda - Aspr / Daappo / Barda Dcma, Office of Assistant Secretary for Preparedness and Response: $63.08M obligated so far for health r&d services; health care services; experimental development. It runs to 2032-03-31, or to 2032-06-30 if every option is exercised.
Key facts · data as of Oct 23, 2026
Source: USAspending.gov prime award records (obligations: money committed, not outlays), data as of Oct 23, 2026.
Cite this page: SpendQuery, Award 75A50124C00052, data as of Oct 23, 2026, https://spendquery.com/award?id=CONT_AWD_75A50124C00052_7505_-NONE-_-NONE-
4J Therapeutics Inc: all federal awards · Department of Health and Human Services: spending · Barda - Aspr / Daappo / Barda Dcma: what it buys
THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO DEMONSTRATE THE VERSATILITY AND EFFICACY OF OUR PROGRAMMABLE ANTIVIRAL TECHNOLOGY PLATFORM BY ASSEMBLING THE PRECLINICAL PACKAGE FOR LNA14, PERFORMING A PHASE 1A STUDY IN HEALTHY ADULT HUMAN SUBJECTS, AND
SpendQuery holds FY2023 on; earlier years are on USAspending.gov.
No subawards reported for this award. Primes report subawards of $30,000 or more; many awards have none.
6 actions since 2024-09-18. Each is a modification or amendment with the money it added or took back.
| Date | Modification | Kind | Amount | What the agency wrote |
|---|---|---|---|---|
| 2026-09-18 | P00005 | Option exercised | $10.60M | THE PURPOSE OF THIS MODIFICATION IS TO UPDATE ARTICLE B.3 ESTIMATED COST-PLUS FIXED FEE CLINS, EXERCISE CLIN4/OPTION 3, AND UPDATE SECTION J-LIST OF ATTACHMENTS: ATTACHMENT #1 STATEMENT OF WORK. |
| 2026-08-21 | P00004 | Option exercised | $14.89M | THE PURPOSE OF THIS MODIFICATION IS TO UPDATE ARTICLE B.3 ESTIMATED COST-PLUS FIXED FEE CLINS, ESTABLISH CLINS 3A (OPTION PERIOD 2A) AND CLIN 3B (OPTION PERIOD 2B), EXERCISE OPTION 3A, AND UPDATE SECTION J - LIST OF ATTACHMENTS, ATTACHMENT #1, STATEM |
| 2025-09-17 | P00003 | Administrative change | $3 | THE PURPOSE OF THIS MODIFICATION IS TO UPDATE ARTICLE G.2 CONTRACTING OFFICER?S REPRESENTATIVE (COR) AND ADD FUNDS REGARDING REQUISITION ASP338221 IN THE AMOUNT OF $2.86 WHICH IS A CORRECTION TO P00001 FOR FUNDING TOTALS ALREADY CONTRACTUALLY AVAILAB |
| 2025-03-18 | P00002 | Administrative change | $0 | THE PURPOSE OF THIS MODIFICATION IS TO 1) UPDATE ARTICLE G.2 CONTRACTING OFFICER'S REPRESENTATIVE (COR), 2) UPDATE ARTICLE G.5 CONTRACT FINANCIAL REPORT, AND 3) UPDATE ARTICLE I.1 FEDERAL ACQUISITION REGULATIONS (FAR) (48 CFR CHAPTER 1) CLAUSES |
| 2025-01-17 | P00001 | Option exercised | $16.99M | THE PURPOSE OF THIS BILATERAL MODIFICATION IS TO EXERCISE OPTION 1 CLIN 0002 TO CONDUCT NON-CLINICAL STUDIES, 2ND NON-GLP TOX; EFFICACY/OFF-TARGET STUDIES AND UPDATE ARTICLE C.1. STATEMENT OF WORK DATED JANUARY 10, 2025. THE OPTION PERIOD OF PERFORMA |
| 2024-09-18 | 0 | $20.60M | THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO DEMONSTRATE THE VERSATILITY AND EFFICACY OF OUR PROGRAMMABLE ANTIVIRAL TECHNOLOGY PLATFORM BY ASSEMBLING THE PRECLINICAL PACKAGE FOR LNA14, PERFORMING A PHASE 1A STUDY IN HEALTHY ADULT HUMAN SUBJECTS, AND |
Source: USAspending.gov prime award transactions and FSRS subaward reports, as loaded by SpendQuery (data as of 2026-10-23). Amounts are obligations (money committed), not outlays. The official record on USAspending.gov ↗